Strong growth and expanding pipeline in the first half of 2024 drive raised guidance

The first six months of 2024 saw excellent sales growth of 9.5% at CER, and a core operating margin of 32.4%. In light of these strong results, we raised our 2024 guidance, with total-sales growth of over 7.0% and a core operating margin of over 30.0%.

We also launched two new medicines in the first half of the year, bringing treatment options to people living with few or no treatment options for devastating conditions. With more regulatory decisions expected in the second half of the year, we hope to bring these innovations to patients around the world.

Our external innovation strategy delivered multiple partnerships with biotechs offering exciting new modalities to explore and bring to patients, including the attractive late-stage asset from Day One Biopharmaceuticals, announced today.

Hear what CEO David Loew has to say about our H1 results and achievements.